Onco-Innovations Enters Agreement with Nucro-Technics for IND-Enabling Studies, Taking a Key Step Toward Human Trials

Onco-Innovations Enters Agreement with Nucro-Technics for IND-Enabling Studies, Taking a Key Step Toward Human Trials

VANCOUVER, BC / ACCESS Newswire / July 4, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into an agreement with Nucro-Technics Inc. ("Nucro-Technics"), dated July 3, 2025, pursuant to…

OncoSil Medical announces completion of patient enrolment in PANCOSIL study - Interventional News

OncoSil Medical has announced the successful completion of patient recruitment for the PANCOSIL study. The PANCOSIL study is an open-label, single-arm phase 1–2 feasibility trial initiated by Amsterdam University Medical Center (Amsterdam UMC) in The Netherlands. The study is evaluating the safety and feasibility of computed tomography (CT)-guided percutaneous radionuclide therapy using the OncoSil device in patients with non-progressive locally…

OncoSil wraps up recruitment for key pancreatic cancer trial

Pancreatic cancer treatment focused OncoSil Medical’s (ASX:OSL) shares stayed flat on Friday as the company revealed it had finally completed recruitment into its ‘PANCOSIL’ trial – despite first receiving ethics approval two years ago. That, perhaps, is part of why investors kept their cash in their proverbial pockets on Friday. What the company is really hoping to do with its trial is accelerate the journey to approvals of its OncoSil device, …